|Articles|April 1, 1999

April 1999
Volume 5
Issue 4

Celecoxib: A COX-2 Inhibitor

Author(s)S. Allyson Andrews, PharmD, Christy K. Wallace, PharmD, Roger L. Davis, PharmD

Download PDF: Celecoxib: A COX-2 Inhibitor

Articles in this issue

about 27 years ago

Article

Medicaid Recipients' Experiences Under Mandatory Managed Care

about 27 years ago

Article

Why Primary Care Physicians Join HMOs

about 27 years ago

Article

Discontinuation Rates of Cholesterol-Lowering Medications

about 27 years ago

Article

The Role of Resource Allocation Models in Selecting Clinical Preventive Services

about 27 years ago

Article

Is Prior Authorization of Topical Tretinoin for Acne Cost Effective?

about 27 years ago

Article

Impact of Therapeutic Interchange from Pravastatin to Lovastatin in a Veterans Affairs Medical Center

about 27 years ago

Article

Targeted Intervention Programs: Creating a Customized Practice Model to Improve the Treatment of Allergic Rhinitis in a Managed Care Population

about 27 years ago

Article

Disease Management of Congestive Heart Failure

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Celecoxib: A COX-2 Inhibitor

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Celecoxib: A COX-2 Inhibitor

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

Zanubrutinib Tops Rivals in Real-World CLL Survival Study